Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy
Guoqing Zhang,1,2 Xiaojuan Zhang,1 Qiuxiang Dong,3 Shuaizhi Kong,2 Lihua Chen,2 Xiaoqing Zhang,1 Jianqing Gao,4 Jie Zhang,1 Baoyue Ding1 1Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, Jiaxing, 314001,...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-08-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/stimuli-responsive-drug-delivery-systems-for-enhanced-melanoma-immunot-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849239225637011456 |
|---|---|
| author | Zhang G Zhang X Dong Q Kong S Chen L Zhang X Gao J Zhang J Ding B |
| author_facet | Zhang G Zhang X Dong Q Kong S Chen L Zhang X Gao J Zhang J Ding B |
| author_sort | Zhang G |
| collection | DOAJ |
| description | Guoqing Zhang,1,2 Xiaojuan Zhang,1 Qiuxiang Dong,3 Shuaizhi Kong,2 Lihua Chen,2 Xiaoqing Zhang,1 Jianqing Gao,4 Jie Zhang,1 Baoyue Ding1 1Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, Jiaxing, 314001, People’s Republic of China; 2College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People’s Republic of China; 3Department of Chemical Drug Inspection, Baoding Institute for Food and Drug Control, Baoding, 071000, People’s Republic of China; 4College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of ChinaCorrespondence: Baoyue Ding, Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, No. 118 Jiahang Road, Jiaxing, Zhejiang, 314001, People’s Republic of China, Tel/Fax +86-0573-83643808, Email lena_310@163.com Jie Zhang, Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, No. 118 Jiahang Road, Jiaxing, Zhejiang, 314001, People’s Republic of China, Tel/Fax +86-0573-83643808, Email zhangjiepharm@zjxu.edu.cnAbstract: Melanoma results in the formation of malignant tumors and is the deadliest form of skin cancer with high mortality rate. Immunotherapy for melanoma has made great breakthroughs in recent decades. However, low patient response rates and side effects due to the immunosuppressive tumor microenvironment (iTME) and tumor heterogeneity limit the clinical application of melanoma immunotherapy. The tumor microenvironment (TME) exhibits characteristics such as weak acidity, hypoxia, and aberrantly expressed proteases. By exploiting these features, researchers have developed stimuli-responsive drug delivery systems (DDSs) to enhance antitumor immune responses in melanoma patients. This review aims to clarify how stimuli-responsive DDSs enhance melanoma immunotherapy and guide their use as therapeutic agents. We summarize the categorization and design of these DDSs, analyze their immune-enhancing pathways, and discuss current challenges and future prospects in the field.Keywords: malignant melanoma, stimuli-responsive, nanoparticles, immunotherapy |
| format | Article |
| id | doaj-art-0e61aefb4ba24022bbce27bf46db4e2a |
| institution | Kabale University |
| issn | 1177-8881 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-0e61aefb4ba24022bbce27bf46db4e2a2025-08-20T04:01:08ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-08-01Volume 19Issue 167896816105551Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma ImmunotherapyZhang G0Zhang X1Dong Q2Kong S3Chen L4Zhang XGao J5Zhang J6Ding B7medical collegeDepartment of Pharmaceutics, College of MedicineChemistry LaboratoryCollege of Pharmaceutical ScienceCollege of Pharmaceutical ScienceInstitute of PharmaceuticsDepartment of PharmaceuticsDepartment of PharmaceuticsGuoqing Zhang,1,2 Xiaojuan Zhang,1 Qiuxiang Dong,3 Shuaizhi Kong,2 Lihua Chen,2 Xiaoqing Zhang,1 Jianqing Gao,4 Jie Zhang,1 Baoyue Ding1 1Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, Jiaxing, 314001, People’s Republic of China; 2College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, People’s Republic of China; 3Department of Chemical Drug Inspection, Baoding Institute for Food and Drug Control, Baoding, 071000, People’s Republic of China; 4College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, People’s Republic of ChinaCorrespondence: Baoyue Ding, Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, No. 118 Jiahang Road, Jiaxing, Zhejiang, 314001, People’s Republic of China, Tel/Fax +86-0573-83643808, Email lena_310@163.com Jie Zhang, Department of Pharmaceutics, Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, College of Medicine, Jiaxing University, No. 118 Jiahang Road, Jiaxing, Zhejiang, 314001, People’s Republic of China, Tel/Fax +86-0573-83643808, Email zhangjiepharm@zjxu.edu.cnAbstract: Melanoma results in the formation of malignant tumors and is the deadliest form of skin cancer with high mortality rate. Immunotherapy for melanoma has made great breakthroughs in recent decades. However, low patient response rates and side effects due to the immunosuppressive tumor microenvironment (iTME) and tumor heterogeneity limit the clinical application of melanoma immunotherapy. The tumor microenvironment (TME) exhibits characteristics such as weak acidity, hypoxia, and aberrantly expressed proteases. By exploiting these features, researchers have developed stimuli-responsive drug delivery systems (DDSs) to enhance antitumor immune responses in melanoma patients. This review aims to clarify how stimuli-responsive DDSs enhance melanoma immunotherapy and guide their use as therapeutic agents. We summarize the categorization and design of these DDSs, analyze their immune-enhancing pathways, and discuss current challenges and future prospects in the field.Keywords: malignant melanoma, stimuli-responsive, nanoparticles, immunotherapyhttps://www.dovepress.com/stimuli-responsive-drug-delivery-systems-for-enhanced-melanoma-immunot-peer-reviewed-fulltext-article-DDDTmalignant melanomastimuli-responsivenanoparticlesimmunotherapy |
| spellingShingle | Zhang G Zhang X Dong Q Kong S Chen L Zhang X Gao J Zhang J Ding B Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy Drug Design, Development and Therapy malignant melanoma stimuli-responsive nanoparticles immunotherapy |
| title | Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy |
| title_full | Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy |
| title_fullStr | Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy |
| title_full_unstemmed | Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy |
| title_short | Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy |
| title_sort | stimuli responsive drug delivery systems for enhanced melanoma immunotherapy |
| topic | malignant melanoma stimuli-responsive nanoparticles immunotherapy |
| url | https://www.dovepress.com/stimuli-responsive-drug-delivery-systems-for-enhanced-melanoma-immunot-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT zhangg stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT zhangx stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT dongq stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT kongs stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT chenl stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT zhangx stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT gaoj stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT zhangj stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy AT dingb stimuliresponsivedrugdeliverysystemsforenhancedmelanomaimmunotherapy |